US · ADVB · MEDICAL - DIAGNOSTICS & RESEARCH
Advanced Biomed Inc. Common Stock (ADVB) intrinsic value and stock valuation
$1.65as of 2026-11-21 · Mkt cap 8.8M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Advanced Biomed Inc. Common Stock DCF and intrinsic value
InvestorsCraft values ADVB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ADVB’s statements →
Advanced Biomed Inc. Common Stock Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2021–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$-90K | -$-2.54M | -$-100K | -$-2.37M | -$-1.84M |
| Net income | -$-100K | -$-2.78M | -$-120K | -$-4.03M | -$-1.84M |
| EPSd | -$-92.59K | -$-2.57M | -$-111.11K | -$-3.73M | -$-1.7M |
| Operating cash flow | -$-180K | -$-2.13M | -$-2.96M | -$-740K | -$-470K |
| Capital expenditure | -$0.00 | -$-70K | -$-210K | -$-1.31M | -$-30K |
| Free cash flow | -$-180K | -$-2.2M | -$-3.18M | -$-2.05M | -$-500K |
| Total assets | $6.51M | $4.46M | $4.6M | $6.71M | $1.01M |
| Total debt | $1.26M | $130K | $240K | $480K | $10K |
| Net debt | -$-1.64M | -$-2.48M | -$-2.38M | -$-4.31M | -$-60K |
| Total equity | $3.48M | $1.66M | $1.31M | $3.49M | $980K |
| Cash and short-term investments | $2.9M | $2.61M | $2.62M | $4.78M | $70K |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $10K | $0.00 | $10K | $0.00 | $0.00 |
| Gross profit | -$-10K | $0.00 | -$-10K | $0.00 | $0.00 |
| Research and development expenses | $30K | $880K | $50K | $1.62M | $1.73M |
| Selling, general and administrative expenses | $60K | $1.26M | $40K | $620K | $40K |
| Other expenses | $0.00 | $400K | $370K | $130K | $60K |
| Operating expenses | $80K | $2.54M | $90K | $2.37M | $1.84M |
| Cost and expenses | $90K | $2.54M | $100K | $2.37M | $1.84M |
| Interest income | $0.00 | $50K | $20K | $0.00 | $0.00 |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $10K | $400K | $10K | $130K | $60K |
| Ebitda | -$-80K | -$-2.14M | -$-90K | -$-2.24M | -$-1.78M |
| Operating income | -$-90K | -$-2.54M | -$-100K | -$-2.37M | -$-1.84M |
| Total other income/expenses, net | -$-10K | -$-240K | -$-20K | -$-1.65M | -$0.00 |
| Income before tax | -$-100K | -$-2.78M | -$-120K | -$-4.03M | -$-1.84M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-100K | -$-2.78M | -$-120K | -$-4.03M | -$-1.84M |
| Weighted average shares outstanding | $1.08M | $1.08M | $1.08M | $1.08M | $1.08M |
| Weighted average diluted shares outstanding | $1.08M | $1.08M | $1.08M | $1.08M | $1.08M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $2.9M | $2.61M | $2.62M | $4.78M | $70K |
| Net receivables | $10K | $10K | $0.00 | $160K | $0.00 |
| Inventory | $0.00 | -$-10K | $0.00 | $0.00 | $0.00 |
| Total current assets | $6.03M | $3.05M | $2.79M | $5.01M | $910K |
| Property, plant and equipment, net | $65.4M | $650K | $950K | $1.23M | $90K |
| Goodwill and intangible assets | $0.00 | $120K | $250K | $410K | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $480K | $1.41M | $1.81M | $1.71M | $90K |
| Total assets | $6.51M | $4.46M | $4.6M | $6.71M | $1.01M |
| Accounts payable | $20K | $620K | $630K | $760K | $0.00 |
| Short-term debt | $1.12M | $60K | $220K | $240K | $10K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $2.89M | $2.73M | $3.28M | $2.99M | $30K |
| Long-term debt | $140K | $60K | $20K | $230K | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $150K | $60K | $20K | $230K | $0.00 |
| Capital lease obligations | $40K | $130K | $240K | $470K | $10K |
| Total liabilities | $3.03M | $2.8M | $3.29M | $3.22M | $30K |
| Common stock | $20K | $20K | $20K | $100K | $10K |
| Retained earnings | -$-19.23M | -$-15.97M | -$-13.19M | -$-9.46M | -$-5.43M |
| Accumulated other comprehensive income (loss) | $1.34M | $1.12M | $800K | $270K | -$-180K |
| Total equity | $3.48M | $1.66M | $1.31M | $3.49M | $980K |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $1.26M | $130K | $240K | $480K | $10K |
| Net debt | -$-1.64M | -$-2.48M | -$-2.38M | -$-4.31M | -$-60K |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-100K | -$-2.78M | -$-3.73M | -$-4.03M | -$-1.84M |
| Depreciation and amortization | $10K | $400K | $370K | $130K | $60K |
| Stock-based compensation | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Change in working capital | -$-90K | $260K | $250K | $1.5M | $1.31M |
| Accounts receivable | $0.00 | $50K | $20K | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$0.00 | $480K | $380K | $910K | $20K |
| Net cash provided by operating activities | -$-180K | -$-2.13M | -$-2.96M | -$-740K | -$-470K |
| Investments in property, plant and equipment | -$0.00 | -$-70K | -$-210K | -$-890K | -$-30K |
| Acquisitions, net | $0.00 | $0.00 | -$-50K | $200K | $0.00 |
| Net cash used for investing activities | -$0.00 | -$-70K | -$-260K | -$-1.08M | -$-30K |
| Common stock issued | $170K | -$0.00 | $1.01M | $6.1M | $700K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $180K | $1.87M | $460K | $6.1M | $700K |
| Net change in cash | $20K | -$-10K | -$-2.16M | $4.72M | $0.00 |
| Cash at end of period | $100K | $2.61M | $2.62M | $4.78M | $70K |
| Operating cash flow | -$-180K | -$-2.13M | -$-2.96M | -$-740K | -$-470K |
| Capital expenditure | -$0.00 | -$-70K | -$-210K | -$-1.31M | -$-30K |
| Free cash flow | -$-180K | -$-2.2M | -$-3.18M | -$-2.05M | -$-500K |
Line items
Line items
Line items
About Advanced Biomed Inc. Common Stock
Advanced Biomed Inc. functions as an investment holding company, primarily dedicated to the research and development of microfluidic biochip technologies. Based in Taiwan, the company leverages these innovations to enhance precision oncology, spanning cancer detection, diagnosis, and treatment. Its diverse product portfolio includes a suite of advanced devices: A+Pre: A fully automated system designed for pre-concentrating diluted blood samples. AC-1000: A rare cell device engineered to address the challenges of detecting cells in hypercoagulable samples from tumor patients. A+SCDrop: A specialized tool for capturing individual circulating tumor cells (CTCs). A+CellScan: An analyzer featuring an immunostaining chip, utilized for the immunostaining and analysis of output from the AC-1000. Beyond standalone devices, Advanced Biomed provides microfluidic biochips, including the A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips, which are integral to delivering assay products and services to cancer patients. The company also offers a comprehensive range of immunochromogenic kits: A+CTCE kit: Used to identify epithelial circulating tumor cells by detecting EpCAM, CK (pan), CD45, and CD14 antibodies. A+CTCM kit: Targets mesenchymal circulating tumor cells through their expression of Vimentin, CD45, and CD14 antibodies. A+EMT kit: Designed for the identification of epithelial-to-mesenchymal circulating tumor cells, focusing on cell-surface Vimentin, CD45, and CD14 antibodies. A+CM kit: Facilitates the detection of tumor-associated macrophages by assessing PD-L1, CD45, and CD14 antibodies. In addition to its current offerings, Advanced Biomed is actively developing A+LCGuard, a promising solution for the early screening of lung cancer. The company further expands its presence by establishing and operating medical clinics in the People's Republic of China. Founded in 2014, Advanced Biomed Inc. maintains its corporate headquarters in New York, New York.
- CEO
- Xiaomin Chen
- Employees
- 31
- Beta
- -0.36
Explore
Frequently asked questions
What is the intrinsic value of Advanced Biomed Inc. Common Stock (ADVB)?
InvestorsCraft does not currently publish an intrinsic value for ADVB. How the IC value is calculated.
Is ADVB undervalued?
InvestorsCraft does not publish an undervaluation signal for ADVB at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.